Investor Relations

Position: Home> Investor Relations> Investment Ecosystem

INVESTMENT ECOSYSTEM

Investment Ecosystem

stq_financeCommitted to serving entrepreneurship and supporting innovation and surrounding the demand for the Group’s strategic development, Financial Ecosystem has focused on controlling the key links along the industry chain and the main creative links along the value chain by working actively on an innovative layout in new industries, models and technologies. In the meantime, as an incubator of innovative medical and health care enterprises, significant efforts are being made to build a professional, market-oriented and regulated open fund management platform, which is to be devoted to investment in the upgrading of medical and health care consumption. Financial Ecosystem also aims to provide support in terms of industry resources domestic and overseas, funding, brand, marketing and management for investing enterprises by relying on its rich industry experience, so as to facilitate the formation of core competitiveness of the invested enterprises, and the establishment of decision-making mechanism for major events.

BAHEAL Investment

Characterized by providing professional assessment and business support, BAHEAL Investment offers support for enterprises with innovation abilities in prevention, diagnosis, treatment and rehabilitation.

Characterized by providing professional assessment and business support, BAHEAL Investment offers support for enterprises with innovation abilities in prevention, diagnosis, treatment and rehabilitation.

More

BAHEAL Pharmaceutical Co., Ltd.

Qingdao BAHEAL Pharmaceutical Co., Ltd., a joint venture founded by BAHEAL Pharmaceutical Group, mainly engages in research & development, production and sales of chemical solid preparations and APIs. Taking technology innovation of preparations and GMP compliance as the core and featuring R&D and production of controlled-release preparations, the company is committed to creating an international platform for manufacturing of generics based on domestic and overseas market including Europe and America. BAHEAL Pharmaceutical has passed the GMP on-site inspection by FDA in October 2016 with zero findings, and this has laid a solid foundation for the internalization of its preparations.

Qingdao BAHEAL Pharmaceutical Co., Ltd., a joint venture founded by BAHEAL Pharmaceutical Group, mainly engages in research & development, production and sales of chemical solid preparations and APIs. Taking technology innovation of preparations and GMP compliance as the core and featuring R&D and production of controlled-release preparations, the company is committed to creating an international platform for manufacturing of generics based on domestic and overseas market including Europe and America. BAHEAL Pharmaceutical has passed the GMP on-site inspection by FDA in October 2016 with zero findings, and this has laid a solid foundation for the internalization of its preparations.

More

Baheal Zhongxin

BAHEAL Zhongxin is an investment management company focusing on medicine and comprehensive health based on market operation. It was founded by BAHEAL Pharmaceutical Group together with many experts in the fields of medicine and comprehensive health. It has been entrusted to manage many investment funds in medicine and comprehensive health.

BAHEAL Zhongxin is an investment management company focusing on medicine and comprehensive health based on market operation. It was founded by BAHEAL Pharmaceutical Group together with many experts in the fields of medicine and comprehensive health. It has been entrusted to manage many investment funds in medicine and comprehensive health.

Tarcine BioMed Inc.

Tarcine BioMed Inc., headquartered in Hong Kong, was co-founded by several US-based scientists and overseas students in 2005. The company is committed to applying America’s cutting-edge technologies in the fields of cytobiology, molecular biology, immunology and the like to clinical practice so as to develop non-invasive and early diagnosis technology for serious diseases. Depending on its professional operation team with excellent R&D competitiveness, it has successively developed “Xinle” high-end early warning system of serious diseases and five products in the fields of myocardial infarction warning, early cancer screening, differential diagnosis of infectious diseases, individualized medication and genetic diagnosis, and quantitative medication monitoring. In addition, it has applied for multiple patents at the national level and marketed a series of products with proprietary intellectual property rights.

Tarcine BioMed Inc., headquartered in Hong Kong, was co-founded by several US-based scientists and overseas students in 2005. The company is committed to applying America’s cutting-edge technologies in the fields of cytobiology, molecular biology, immunology and the like to clinical practice so as to develop non-invasive and early diagnosis technology for serious diseases. Depending on its professional operation team with excellent R&D competitiveness, it has successively developed “Xinle” high-end early warning system of serious diseases and five products in the fields of myocardial infarction warning, early cancer screening, differential diagnosis of infectious diseases, individualized medication and genetic diagnosis, and quantitative medication monitoring. In addition, it has applied for multiple patents at the national level and marketed a series of products with proprietary intellectual property rights.

More